Scholarlink

Background <p>Bipolar disorder (BD)- a leading cause of disability in young adults- lacks reliable biomarkers. This case–control study investigates soluble urokinase plasminogen activator receptor (suPAR), a protein bridging inflammation and neural repair, as a novel biomarker candidate among Egyptian patients with BD.</p> Methods <p>We compared 48 BD patients (DSM-5- diagnosis, confirmed via SCID-5-CV) and 48 age-/sex-matched controls. Sociodemographic data were collected from all participants using a standardized questionnaire, with additional clinical variables assessed exclusively in the bipolar disorder group. Symptom severity was assessed using Arabic-validated Hamilton Depression (HDRS-17) and Young Mania Rating Scale (YMRS). Fasting serum suPAR levels were quantified via ELISA.</p> Results <p>BD patients showed&#xa0;significantly lower suPAR&#xa0;versus controls, without significant associations with key clinical characteristics (as hospitalization, suicidality). ROC analysis identified suPAR ≤ 110.113&#xa0;ng/ml with an optimal diagnostic cutoff (AUC = 0.758), with&#xa0;83.3% sensitivity, 60.4% specificity, and 71.9% accuracy.</p> Conclusions <p>Reduced suPAR represents a potential&#xa0;trait biomarker&#xa0;in BD, reflecting impaired neural regeneration rather than episodic symptoms. It may have a clinical utility for early detection, while its role in axonal repair highlights new therapeutic targets.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The relationship between Urokinase-Plasminogen Activator Receptor (UPAR) and bipolar disorder: a case–control study, Egypt

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月4日

查看全文
  • Usama Mahmoud Youssef,
  • Yasser Mohamed Raya,
  • Mohammad Gamal Sehlo,
  • Osama Mohamed Gado,
  • Fayza Mohammed Hussien,
  • Mervat Said

摘要

Background

Bipolar disorder (BD)- a leading cause of disability in young adults- lacks reliable biomarkers. This case–control study investigates soluble urokinase plasminogen activator receptor (suPAR), a protein bridging inflammation and neural repair, as a novel biomarker candidate among Egyptian patients with BD.

Methods

We compared 48 BD patients (DSM-5- diagnosis, confirmed via SCID-5-CV) and 48 age-/sex-matched controls. Sociodemographic data were collected from all participants using a standardized questionnaire, with additional clinical variables assessed exclusively in the bipolar disorder group. Symptom severity was assessed using Arabic-validated Hamilton Depression (HDRS-17) and Young Mania Rating Scale (YMRS). Fasting serum suPAR levels were quantified via ELISA.

Results

BD patients showed significantly lower suPAR versus controls, without significant associations with key clinical characteristics (as hospitalization, suicidality). ROC analysis identified suPAR ≤ 110.113 ng/ml with an optimal diagnostic cutoff (AUC = 0.758), with 83.3% sensitivity, 60.4% specificity, and 71.9% accuracy.

Conclusions

Reduced suPAR represents a potential trait biomarker in BD, reflecting impaired neural regeneration rather than episodic symptoms. It may have a clinical utility for early detection, while its role in axonal repair highlights new therapeutic targets.